A randomised controlled trial investigating the pharmacodynamic effect of TicagrElor Monotherapy on PLATElet reactivity in patients with coronary artery disease

Trial Profile

A randomised controlled trial investigating the pharmacodynamic effect of TicagrElor Monotherapy on PLATElet reactivity in patients with coronary artery disease

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs Ticagrelor (Primary) ; Aspirin
  • Indications Coronary artery disease
  • Focus Pharmacodynamics
  • Acronyms TEMPLATE
  • Most Recent Events

    • 16 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 31 Mar 2016 Planned End Date changed from 1 Dec 2016 to 14 Dec 2018 as reported by ISRCTN record.
    • 31 Mar 2016 Planned initiation date changed from 15 Mar 2014 to 14 Dec 2016 as per ISRCTN record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top